Professor Hirofumi Sawa, Director of this IVReD, and Visiting Professor Akihiko Sato of the Clinical Development Department were involved in the development of Xocova, Japan’s first new coronavirus treatment. Shionogi & Co., Ltd. applied for an additional indication for the prevention of COVID-19 in Japan. Please see the page below for details.